If this message does not display properly, please click here to launch your browser
| The Targeted Cancer Therapies Industry: Will It Become a Victim of Its Own Success? — A Webinar from Decision Resources | |||
Based on our report entitled, Strategic Overview of the Targeted Cancer Therapies Marketplace, Decision Resources is offering an exclusive webinar entitled The Targeted Cancer Therapies Industry: Will It Become a Victim of Its Own Success? Because this webinar will feature major report findings, it is ONLY available to purchasers of this report. Strategic Overview reports are a new offering within the Spectrum franchise. Please contact us to learn how you can purchase this report and attend the webinar. The success of marketed targeted therapies has had an enormous impact on the treatment of cancer, and targeted drugs such as Novartis’s Gleevec and Genentech/Roche/Chugai’s Rituxan, Herceptin and Avastin continue to generate blockbuster sales that are drawing more and more pharmaceutical companies into the field. The targeted therapy pipeline is full of novel compounds, and drug developers will face intense competition and pressure to differentiate their products to gain reimbursement and claim market share. However, a recent survey of U.S. oncologists found considerable concern about the cost of targeted therapies. Drug manufacturers will need to prepare for a more hostile reimbursement environment in the future. This webinar, presented by Decision Resources Analyst Barbara M. Bolten, M.S., MBA will discuss:
Ms. Bolten and Pricing and Reimbursement Research Director Neil Grubert, M.A., will conduct a live Q & A session after the presentation. Registration The Targeted Cancer Therapies Industry: Will It Become a Victim of Its Own Success? February 24, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this report and attend the webinar, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
Barbara M. Bolten, M.S., MBA, is a senior program manager at Decision Resources; as leader of Spectrum’s Discovery and Innovation: Technologies, Strategies, and Dealmaking portfolio, Ms. Bolten focuses on early-stage drug discovery, emerging technologies and opportunities and dealmaking in the biotech and pharmaceutical industries. She has worked for Decision Resources for 12 years; previously, she was employed as director, licensing, at Mitotix, Inc.; as director of marketing and general manager, new product programs, at Owl Scientific, Inc.; and in research positions at Biotechnica International and the Department of Microbiology and Molecular Biology at Tufts University. Ms. Bolten received her B.S. in biology and M.S. in biology from Tufts University and her MBA from the High Technology MBA program of Northeastern University. 